Onno Stolpe - Galapagos CEO

GLPGF Stock  USD 26.20  9.32  26.24%   

CEO

Mr. Onno van de Stolpe has served as Chief Executive Officer, Executive Director, Chairman of the Executive Committee of Galapagos NV since June 1999. He founded Galapagos in 1999 while he was Managing Director Genomics at Introgene . Prior to joining Introgene in 1998, he was Managing Director of Molecular Probes Europe. He established this European headquarters after joining Molecular Probes in the United States. Previously, he worked for the Netherlands Foreign Investment Agency in California, where he was responsible for recruiting biotech and medical device companies to locate in the Netherlands. Mr. van de Stolpe started his career as Manager Business Development at MOGEN in Leiden. He has previously served as member of the supervisory board of the Stichting Institute for Human Organ and Disease Model Technologies and as a member of the board of directors of DCPrime B.V since 1999.
Age 58
Tenure 25 years
Phone32 1 534 29 00
Webhttps://www.glpg.com
Onno van de Stolpe received a MS degree from the Agricultural in Wageningen.

Galapagos Management Efficiency

The company has return on total asset (ROA) of (0.0119) % which means that it has lost $0.0119 on every $100 spent on assets. This is way below average. Galapagos' management efficiency ratios could be used to measure how well Galapagos manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 24.05 M in total debt with debt to equity ratio (D/E) of 0.01, which may suggest the company is not taking enough advantage from borrowing. Galapagos NV has a current ratio of 8.07, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Galapagos until it has trouble settling it off, either with new capital or with free cash flow. So, Galapagos' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Galapagos NV sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Galapagos to invest in growth at high rates of return. When we think about Galapagos' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 2 records

CEO Age

Brian PedlarCovalon Technologies
N/A
Gilles GagnonCeapro Inc
62
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium. Galapagos Genomics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 1344 people. Galapagos NV [GLPGF] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC).

Management Performance

Galapagos NV Leadership Team

Elected by the shareholders, the Galapagos' board of directors comprises two types of representatives: Galapagos inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Galapagos. The board's role is to monitor Galapagos' management team and ensure that shareholders' interests are well served. Galapagos' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Galapagos' outside directors are responsible for providing unbiased perspectives on the board's policies.
Rajesh Parekh, Non-Executive Chairman of the Board
Andre Hoekema, Sr. VP of Corporate Devel.
Katrine Bosley, Independent Non-Executive Director
John Montana, Managing Argenta
Walid AbiSaab, Member of the Executive Committee, Chief Medical Officer
Marieke Vermeersch, Head Communication
Howard Rowe, Non-Executive Independent Director
Bob Rajan, Non-Executive Independent Director
Harrold Barlingen, Non-Executive Director
Raj Parekh, Non-Executive Chairman of the Board
Elizabeth Goodwin, VP Corporate Communications & Investor Relations
Mary Kerr, Non-Executive Independent Director
Michele MBA, Chief Board
Piet Wigerinck, Chief Scientific Officer
Chantal Tasset, Head Devel
Sofie Gijsel, Head Relations
MBA MBA, COO Pres
Bart Filius, CFO
Christine Mummery, Non-Executive Independent Director
Werner Cautreels, Non-Executive Independent Director
Onno Stolpe, Co-Founder, CEO, Managing Director and Executive Director

Galapagos Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Galapagos a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galapagos NV. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.
Note that the Galapagos NV information on this page should be used as a complementary analysis to other Galapagos' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Complementary Tools for Galapagos Pink Sheet analysis

When running Galapagos' price analysis, check to measure Galapagos' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galapagos is operating at the current time. Most of Galapagos' value examination focuses on studying past and present price action to predict the probability of Galapagos' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galapagos' price. Additionally, you may evaluate how the addition of Galapagos to your portfolios can decrease your overall portfolio volatility.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Please note, there is a significant difference between Galapagos' value and its price as these two are different measures arrived at by different means. Investors typically determine if Galapagos is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galapagos' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.